IDEAYA Biosciences shares are trading higher after the company announced topline results from its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA-A*A2:01-negative metastatic uveal melanoma met its primary endpoint.